CDK8 was initially identified as an oncogenerequired for β-catenin-inducedtranscription in colorectal cancer and later implicated in regulatingthe AP1 family of transcription factors downstream of RAS/RAF/MEKsignaling.,,, Consistent with these roles in colorectalcancer, GSEA confirmed CDK8’s role in oncogenic pathways, showinginhibition of β-catenin/TCF, KRAS/MAPK, and ATF target genesfollowing inhibitor treatment or loss of both Mediator kinases incolorectal cancer cells dependent on oncogenic beta-catenin and KRAS/BRAFsignaling. Here, KRAS is linked to cancer.